

Freedom of Information Request: Our Reference CTMUHB_19_23

You asked:

I am analysing the usage of **intra-vitreous injections or implants** by the NHS. I would greatly appreciate if you could answer the following questions:

1. How many of the following intra-vitreous injections/implants has your trust administered in the four-month period from September to December 2022:

- **Aflibercept** - 1712
- **Bevacizumab** - 19
- **Brolucizumab** - 0
- **Dexamethasone** - 54
- **Faricimab** - 201
- **Ranibizumab – Lucentis** - 10
- **Ranibizumab – Ongavia** - 0

2. Please provide the number of injections/implants by eye condition for the four-month period from September to December 2022.

Number of Injections/Implants: September - December 2022

Treatment	Eye Conditions		
	Wet Age-Related Macular Degeneration (wAMD)	Diabetic Macular Oedema (DMO)	Retinal Vein Occlusion (RVO)
Aflibercept			
Bevacizumab			
Brolucizumab			
Dexamethasone			
Faricimab			
Ranibizumab - Lucentis			
Ranibizumab - Ongavia			

We can confirm that this level of information is not captured on our Medicines Management system. The information you require would be recorded within an individual patient's health record as part of their ongoing care. To provide you with this information, would require a manual trawl through all the Ophthalmology patients treated within this timeframe and would significantly exceed the 18 hours' time and £450 cost limit set out within Section 12 of the Freedom of Information Act.